Bayer Nails Down Deal To Share Ex-U.S. Rights For Wet AMD Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement with Regeneron includes joint development and commercialization of VEGF-Trap Eye for wet AMD and diabetic macular edema.
You may also be interested in...
Alcon Grabs Ex-U.S. Rights To ThromboGenics' Retina Adhesion Therapy Ocriplasmin In $500 Mil. Deal
Novartis' ophthalmic unit Alcon will collaborate with Belgium's ThromboGenics on the marketing and future development of the vitreomacular adhesion therapy, ocriplasmin.
Bayer/Regeneron Phase III Will Study Eight-Week Dosing With VEGF Trap-Eye
Non-inferiority trial will compare the VEGF Trap-Eye candidate to Genentech’s Lucentis.
Bayer/Regeneron Phase III Will Study Eight-Week Dosing With VEGF Trap-Eye
Non-inferiority trial will compare the VEGF Trap-Eye candidate to Genentech’s Lucentis.